Ocuphire Pharma announced the appointment of Joseph Schachle, M.B.A., into the newly created role of Chief Operating Officer, COO, effective today. Schachle was most recently Chief Operating Officer of Opus Genetics, a gene therapy company focused on rare, inherited retinal diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCUP:
- Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
- Ocuphire Pharma expects cash to fund operations into 2025
- Ocuphire Pharma reports Q3 EPS 25c, consensus (22c)
- Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update